Drugs for Thyroid Cancer, Nonmedullary, 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 207)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Paclitaxel |
Approved, Vet_approved |
Phase 4 |
|
33069-62-4 |
36314 |
Synonyms:
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7 Epi taxol
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-epi-Paclitaxel
7-Epipaclitaxel
7-Epi-paclitaxel
7-epi-Taxol
7-Epitaxol
7-Epi-taxol
AB00513812
ABI 007
abi-007
ABI007
ABI-007
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
AC1L1IOG
AC1L1VJI
AC1L9AVF
AC-675
ACon1_002231
albumin-bound paclitaxel
Ambotz33069-62-4
ANX-513
Anzatax
Asotax
BIDD:PXR0046
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
Bris taxol
Bristaxol
BSPBio_000290
BSPBio_001152
BSPBio_002614
C07394
C466458
C47H51NO14
Capxol
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
cMAP_000068
CPD-8718
D00491
DB01229
DHP-107
DHP-208
DivK1c_000441
DRG-0190
DTS-301
Ebetaxel
EmPAC
Epitaxol
EU-0101201
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
|
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LipoPac
LMPR0104390001
Lopac0_001201
LS-31070
MBT 0206
MEGxp0_001940
Micellar Paclitaxel
Mitotax
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
MPI-5018
nab-paclitaxel
Nanotaxel
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
NCI60_000601
Neuro_000060
NINDS_000441
NK 105
Nova-12005
NP-010981
NSC 125973
NSC125973
NSC-125973
NSC358882
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
paclitaxel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paclitaxel, (4 alpha)-isomer
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S1150_Selleck
S-8184 Paclitaxel Injectable Emulsion
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
Spectrum_001536
SPECTRUM1503908
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
ST50306996
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TaxAlbin
Taxol
TAXOL
TAXOL (TN)
Taxol a
Taxol A
Taxol Konzentrat
TAXOL, 10-EPI,
Taxol, bris
Taxol.RTM. (Registered Trademark)
TXL
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
weekly paclitaxel
Xorane
Yewtaxan
|
|
2 |
|
Aztreonam |
Approved |
Phase 4 |
|
78110-38-0 |
5742832 5362041 |
Synonyms:
(Z,)-2-((((2-amino-4-Thiazolyl)(((2S,3S,)-2-methyl-4-oxo-1-sulfO-3-azetidinyl)carbamoyl)methylene)amino)oxy)-2-methylpropionate
(Z,)-2-((((2-amino-4-Thiazolyl)(((2S,3S,)-2-methyl-4-oxo-1-sulfO-3-azetidinyl)carbamoyl)methylene)amino)oxy)-2-methylpropionic acid
(Z,)-2-((((2-Amino-4-thiazolyl)(((2S,3S,)-2-methyl-4-oxo-1-sulfo-3-azetidinyl)carbamoyl)methylene)amino)oxy)-2-methylpropionic acid
(Z,)-2-((((2-amino-4-Thiazolyl)(((2S,3S,)-2-methyl-4-oxo-1-sulphO-3-azetidinyl)carbamoyl)methylene)amino)oxy)-2-methylpropionate
(Z,)-2-((((2-amino-4-Thiazolyl)(((2S,3S,)-2-methyl-4-oxo-1-sulphO-3-azetidinyl)carbamoyl)methylene)amino)oxy)-2-methylpropionic acid
[2S-[2alpha,3beta(Z)]]-2-[[[1-(2-Amino-4-thiazolyl)-2-[(2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino]-2-oxoethylidene]amino]oxy]-2-methylpropanoic acid
2-({[(1Z)-1-(2-amino-1,3-thiazol-4-yl) -2- {[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino} -2- oxoethylidene]amino}oxy)-2-methylpropanoic acid
2-({[(1Z)-1-(2-amino-1,3-thiazol-4-yl)-2-{[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino}-2-oxoethylidene]amino}oxy)-2-methylpropanoic acid
2-[(Z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxy-2-methylpropanoic acid
78110-38-0
AC1NX3U2
AC-4330
Ambap78110-38-0
Az threonam
Azactam
AZT
Azthreonam
Az-threonam
aztreonam
Aztreonam
Aztréonam
Aztreonam esteve brand
Aztreonam squibb brand
Aztreonamum
BIDD:GT0765
|
BPBio1_000121
BRD-K62607865-001-03-0
Bristol myers squibb brand OF aztreonam
Bristol-myers squibb brand OF aztreonam
BSPBio_000109
CHEBI:161680
CHEMBL158
CID5742832
Esteve brand OF aztreonam
HMS1568F11
HMS2090K09
MolPort-003-886-345
Monobactam, SQ 26776, Squibb 26776, Aztreonam
NCGC00179656-01
NSC646279
Prestwick_914
Prestwick2_000185
Prestwick3_000185
Primbactam
S1505_Selleck
Sanofi winthrop brand OF aztreonam
SQ-26776
Squibb brand OF aztreonam
Urobactam
|
|
3 |
|
Montelukast |
Approved |
Phase 4 |
|
158966-92-8 |
5281040 |
Synonyms:
(R-(e))-1-(((1-(3-(2-(7-chloro-2-Quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetate
(R-(e))-1-(((1-(3-(2-(7-chloro-2-Quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid
(R-(E))-1-(((1-(3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid
{1-[({(1R)-1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetic acid
1-((((1R)-1-(3-((1E)-2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid
1-[[[(1 R)-1-[3-[(1E)-2-(7-chloro-2-Quinolinyl)ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropaneacetate
1-[[[(1 R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropaneacetic acid
1-[[[(1 R)-1-[3-[(1E)-2-(7-chloro-2-Quinolinyl)ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropaneacetic acid
1-[[[(1 R)-1-[3-[(1E)-2-(7-chloro-2-Quinolinyl)ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulphanyl]methyl]cyclopropaneacetate
1-[[[(1 R)-1-[3-[(1E)-2-(7-chloro-2-Quinolinyl)ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulphanyl]methyl]cyclopropaneacetic acid
151767-02-1 (sodium)
158966-92-8
2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid
AC1NQXXW
Apxi toxin
BIDD:GT0394
Brondilat
Brondilat (TN)
C07482
C35H36ClNO3S
Cahill may roberts brand OF montelukast sodium
CHEBI:50730
CHEMBL787
CID5281040
|
D08229
DB00471
HMS2089D07
HSDB 7582
LS-173539
Merck brand OF montelukast sodium
Merck frosst brand OF montelukast sodium
Merck sharp and dohme brand OF montelukast sodium
MK 0476
MK-0476
Montair
montelukast
Montelukast
Montélukast
Montelukast (INN)
Montelukast [INN:BAN]
Montelukast sodium
Montelukastum
Singulair
Singular
sodium 1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropylacetate
Sodium 1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropylacetate
UNII-MHM278SD3E
|
|
4 |
|
Theophylline |
Approved |
Phase 4 |
|
58-55-9 |
2153 |
Synonyms:
1,3 Dimethylxanthine
1,3-dimethyl-7H-purine-2,6-dione
1,3-Dimethyl-7H-purine-2,6-dione
1,3-dimethylxanthine
1,3-Dimethylxanthine
111079-49-3
1H-purine-2,6-dione
2a3a
3,7-dihydro-1,3-Dimethyl-1H-purine-2,6-dione
46157-00-0
56645-32-0
58-55-9
75448-53-2
AB00052106
AC1L1D1F
AC-20328
Accurbron
Acet-theocin
Aerobin
Aerolate
Aerolate III
Aerolate SR
Afonilm
Afonilum
Afonilum retard
Afonilum Retard
AI3-50216
AKOS000120961
aminophylline
Aminophylline
Anhydrous, theophylline
Aquaphyllin
Armophylline
Asbron
Asmalix
Asmax
Austyn
BCBcMAP01_000071
BIDD:ER0557
BIDD:GT0151
Bilordyl
BPBio1_000791
BPBio1_001041
Bronchodid Duracap
Bronchoparat
Bronchoretard
Bronkodyl
Bronkodyl SR
Bronkotabs
BSPBio_000719
BSPBio_000945
BSPBio_002363
C07130
C7H8N4O2
CCRIS 4729
Cetraphylline
CHEBI:28177
CHEMBL190
Choledyl sa
Choledyl SA
Chronophyllin
CID2153
Constant T
ConstantT
Constant-T
CPD000058537
CPD-12479
CT Arzneimittel brand OF theophylline sodium glycinate
ct, theo von
CT, theo Von
CT-Arzneimittel brand OF theophylline sodium glycinate
D00371
D013806
DB00277
Diffumal
Dimethylxanthine
Diphyllin
DivK1c_000203
Doraphyllin
Duraphyl
Duraphyllin
Dyspne-inhal
Egifilin
EINECS 200-385-7
Elixex
Elixicon
Elixomin
Elixophyllin
Elixophyllin (TN)
Elixophyllin SR
Elixophyllin(e)
Elixophylline
Etheophyl
Euphylline
Euphylong
Fameasan brand OF theophylline sodium glycinate
Fujisawa brand OF theophylline sodium glycinate
Glycinate, theophylline sodium
Glycine theophyllinate
GS 2591A
HMS1921E03
HMS2089A06
HMS2092M05
HMS500K05
HSDB 3399
Hylate
IDI1_000203
KBio1_000203
KBio2_001518
KBio2_004086
KBio2_006654
KBio3_001583
KBioGR_000785
KBioSS_001518
L000595
Labid
LaBID
Labophylline
Lanophyllin
LASMA
Liquophylline
Liquorice
Lodrane
Lopac0_000014
LS-241
Maphylline
Medaphyllin
MLS000069390
MLS002152943
MLS002153487
MolPort-001-002-058
MolPort-001-737-342
Monospan
Mudrane
Mundipharma brand OF theophylline sodium glycinate
NCGC00018117-01
NCGC00018117-16
NCGC00022112-03
NCGC00022112-04
NCGC00022112-05
NCGC00022112-07
NCGC00022112-08
NCGC00022112-09
NCGC00022112-10
NCGC00022112-11
nchembio.273-comp2
NCI60_001736
NINDS_000203
NSC 2066
NSC2066
Nuelin
Nuelin S.A
Nuelin s.a.
Nuelin S.A.
Nuelin SA
Optiphyllin
Parkophyllin
PDSP1_001018
PDSP1_001234
PDSP2_001002
PDSP2_001218
Physpan
Prestwick0_000820
Prestwick0_000873
Prestwick1_000820
Prestwick1_000873
Prestwick2_000820
Prestwick2_000873
|
Prestwick3_000820
Prestwick3_000873
Pro-vent
Pseudotheophylline
Pulmidur
Pulmo-Timelets
Quibron
Quibron T
Quibron T SR
Quibron t/sr
Quibron T/SR
Quibron TSR
Quibron T-SR
Quibron-T
Quibron-t (TN)
Quibron-t/sr
Quibron-T/SR
Respbid
Respicur
Respid
S1621_Selleck
SAM002554935
slo Phyllin
Slo Phyllin
slo-Bid
Slo-bid
slo-Phyllin
Slo-phyllin
SloPhyllin
SMP1_000291
SMR000058537
Sodium glycinate, theophylline
Solosin
Somophyllin CRT
Somophyllin T
Somophyllin-CRT
Somophyllin-DF
Somophyllin-t
SomophyllinT
Somophyllin-T
SPBio_000823
SPBio_002640
SPBio_002866
Spectrum_001038
SPECTRUM1500568
Spectrum2_000842
Spectrum3_000672
Spectrum4_000353
Spectrum5_001232
Spophyllin retard
ST024762
STK397040
Sustaire
Synophylate
Synophylate-l.a. cenules
T0179
T1633_SIGMA
T4924_SIGMA
T7770_SIGMA
T9031_SIGMA
Talotren
Tefamin
Telbans Dry Syrup
Telb-DS
Teocen 200
Teofilina
Teofilina [Polish]
Teofyllamin
Teolair
Teonova
Teosona
Tesona
Theacitin
Theal tabl.
Theal tablets
theo 24
Theo 24
theo Dur
Theo Dur
theo von ct
theo Von CT
Theo-11
theo-24
Theo24
Theo-24
Theo-24 (TN)
Theobid
Theobid Duracap
THEOBID JR
Theobid jr.
Theobid Jr.
Theochron
Theocin
Theoclair-SR
Theoclear
Theoclear 80
Theoclear l.a.-130
Theoclear L.A.-130
Theoclear la
Theoclear LA
Theoclear-200
Theoclear-80
Theoconfin continuous
Theocontin
Theodel
Theodrip
Theo-DS
theo-Dur
Theodur
Theo-dur
Theodur Dry Syrup
Theodur G
Theodur G (TN)
theo-Dur-sprinkle
Theo-Dur-Sprinkle
Theofol
Theograd
Theokin
Theolair
Theolair (TN)
Theolair-SR
Theolix
Theolixir
Theon
Theona P
Theonite
Theo-Nite
Theo-Organidin
Theopek
Theophyl
Theophyl-225
Theophyline
Theophyllin
Theophyllinate, glycine
theophylline
Theophylline (JP15)
Theophylline anhydrous
Theophylline sodium glycinate
Theophylline, anhydrous
Theophylline-[8-3H
Theophylline-SR
Theophyl-SR
Theoplus
Theo-Sav
Theospan
Theostat
Theostat 80
Theotard
Theovent
T-Phyl
Uni-dur
Uni-Dur
Unifyl
UNII-0I55128JYK
Unilong
Uniphyl
Uniphyl (TN)
Uniphyllin
Uniphyllin continus
Uniphylline
UPCMLD-DP123
UPCMLD-DP123:001
von ct, theo
Von CT, theo
X 115
Xanthium
Xantivent
ZINC18043251
|
|
5 |
|
Anti-Bacterial Agents |
|
Phase 4 |
|
|
|
6 |
|
Antibiotics, Antitubercular |
|
Phase 4 |
|
|
|
7 |
|
Albumin-Bound Paclitaxel |
|
Phase 4 |
|
|
|
8 |
|
Tubulin Modulators |
|
Phase 4 |
|
|
|
9 |
|
Antimitotic Agents |
|
Phase 4 |
|
|
|
10 |
|
Hormones |
|
Phase 4 |
|
|
|
11 |
|
Hormone Antagonists |
|
Phase 4 |
|
|
|
12 |
|
Adrenergic Agents |
|
Phase 4 |
|
|
|
13 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
14 |
|
Adrenergic beta-Agonists |
|
Phase 4 |
|
|
|
15 |
|
Respiratory System Agents |
|
Phase 4 |
|
|
|
16 |
|
Phosphodiesterase Inhibitors |
|
Phase 4 |
|
|
|
17 |
|
Salmeterol xinafoate |
|
Phase 4 |
|
94749-08-3 |
56801 |
Synonyms:
(+-)-4-Hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-m-xylene-alpha,alpha'-diol 1-hydroxy-2-naphthoate (salt)
(+/-) 4-Hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]m-ethyl]-1,3-benzenedimethanol xinafoate
1,3-Benzenedimethanol, 4-hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-, (+-)-, 1-hydroxy-2-naphthalenecarboxylate (salt)
1-hydroxynaphthalene-2-carboxylic acid
2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol
89365-50-4 (Parent)
94749-08-3
AC1L1LPS
Arial
Asmerole
Beglan
Betamican
Bio-0096
C25H37NO4.C11H8O3
CHEMBL1082607
CID56801
D00687
Dilamax
EU-0101100
GR 33343 G
GR 33343X xinafoate
GR-33343 G
|
Inaspir
LS-94516
MLS001332577
MLS001332578
MolPort-003-850-218
NCGC00094372-01
NCGC00094372-02
NCGC00094372-03
NCGC00094372-04
S5068_SIGMA
Salmetedur
Salmeterol 1-hydroxy-2-naphthoate
salmeterol xinafoate
Salmeterol xinafoate (JAN/USAN)
Salmeterol xinafoate [USAN]
Serevent (TN)
Serevent diskus
Serevent Inhaler and Disks
SMR000875207
Ultrabeta
UNII-6EW8Q962A5
|
|
18 |
|
Leukotriene Antagonists |
|
Phase 4 |
|
|
|
19 |
|
Vasodilator Agents |
|
Phase 4 |
|
|
|
20 |
|
Anti-Asthmatic Agents |
|
Phase 4 |
|
|
|
21 |
|
Adrenergic Agonists |
|
Phase 4 |
|
|
|
22 |
|
Bronchodilator Agents |
|
Phase 4 |
|
|
|
23 |
|
Docetaxel |
Approved, Investigational |
Phase 3 |
|
114977-28-5 |
148124 |
Synonyms:
(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate
01885_FLUKA
114977-28-5
4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
AC1L3WHJ
AC-383
ANX-514
BIND-014
C11231
CHEBI:4672
CHEMBL92
CID148124
D07866
DB01248
docetaxel
Docetaxel
Docetaxel (INN)
docetaxel 114977-28-5
Docetaxel anhydrous
Docetaxel hydrate
Docetaxel trihydrate
Docetaxel, trihydrate
Docetaxel, Trihydrate
Docetaxol
|
EmDOC
HMS2089K08
InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5
MolPort-003-847-005
nchembio.188-comp8
nchembio.2007.34-comp7
nchembio.573-comp11
nchembio853-comp8
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-Boc-10-deacetyl taxol
N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol
NSC-628503
PSMA-targeted docetaxel nanoparticle
RP-56976
SDP-014
Taxoltere metro
Taxotere
Taxotere (TN)
Taxotere(R)
TXL
XRP-6976L
|
|
24 |
|
Zoledronic Acid |
Approved |
Phase 3 |
|
118072-93-8 |
68740 |
Synonyms:
(1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonate
(1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid
(1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid
(1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid
(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonate
(1-hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
(1-hydroxy-2-imidazol-1-yl-phosphonoethyl)phosphonic acid monohydrate
[1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid)
118072-93-8
2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid
2-(imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid
2-(Imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid
AC-1092
AC1L2ACJ
AC1Q6RN3
ácido zoledrónico
Aclasta
AKOS005145739
Anhydrous Zoledronic Acid
BIDD:GT0292
BIDD:PXR0134
Bio-0112
Bisphosphonate 3
C088658
CGP 42446
CGP 42'446
CGP 42446A
CGP-42446
CGP-42'446
CHEBI:46557
CHEMBL924
CID68740
|
D08689
DB00399
FT-0082657
HMS2089O09
I06-0710
KS-1132
LS-181815
MolPort-002-885-874
MolPort-003-850-890
NCGC00159521-02
NCGC00159521-03
Novartis brand of zoledronic acid
Novartis brand OF zoledronic acid
NSC721517
Reclast
Reclast (TN)
S00092
S1314_Selleck
UNII-70HZ18PH24
Zol
ZOL
Zoledronate
Zoledronic acid
Zoledronic acid (INN)
Zoledronic acid [USAN:INN]
Zoledronic Acid Anhydrous
Zoledronic Acid, Anhydrous
Zometa
Zometa (Novartis)
Zometa (TN)
Zometa Concentrate
Zometa, Zomera, Aclasta and Reclast, Zoledronic Acid
|
|
25 |
|
Prazosin |
Approved |
Phase 3 |
|
19216-56-9 |
4893 |
Synonyms:
[3H]-Prazosin
[4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-(2-furyl)methanone
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl](furan-2-yl)methanone
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(furan-2-yl)methanone
1-(3-Amino-6,7-dimethoxy-2- quinazolinyl)-4-(2-furanyl-carbonyl)piperazine hydrochloride
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl) piperazine
1-(4-amino-6,7-Dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine
19216-56-9
2-(4-(2-Furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline
2-[4-(2-furoyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine
4-(4-Amino-6,7-dimethoxyquinazolin-2-yl)piperazinyl 2-furyl ketone
5-25-13-00365 (Beilstein Handbook Reference)
AB00053528
AC1L1J6T
AKOS000310009
BCBcMAP01_000227
Bio1_000365
Bio1_000854
Bio1_001343
Bio2_000358
Bio2_000838
BPBio1_001006
BRD-K49111258-001-02-8
BRD-K49111258-003-05-7
BRN 0768345
BSPBio_000914
BSPBio_001036
BSPBio_002221
C07368
C19H21N5O4
CAS-19237-84-4
CHEBI:8364
CHEMBL2
CID4893
CP-12299
D08411
DB00457
DivK1c_000375
Douglas brand OF prazosin hydrochloride
EINECS 242-885-8
Furazosin
HCL, Prazosin
HMS1362D17
HMS1792D17
HMS1990D17
HMS2089G09
HSDB 3298
Hydrochloride, prazosin
IDI1_000375
IDI1_002113
Justac
KBio1_000375
KBio2_000376
KBio2_001302
KBio2_002944
KBio2_003870
KBio2_005512
KBio2_006438
KBio3_000731
KBio3_000732
KBio3_001721
KBioGR_000376
|
KBioGR_000965
KBioSS_000376
KBioSS_001302
L000666
Lentopres
LS-140002
Minipress
Minipress (TN)
Minipress Xl
MolPort-000-891-036
NCGC00016740-01
NCGC00016740-02
NCGC00016740-03
NCGC00016740-14
NCGC00024324-02
NCGC00024324-04
NCGC00024324-05
NCGC00024324-06
NCGC00024324-07
NCGC00024324-08
NCGC00024324-09
NCI60_002417
NINDS_000375
Oprea1_314778
Pfizer brand OF prazosin hydrochloride
Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)- (9CI)
Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)- (8CI)
Pratsiol
Prazocin
prazosin
Prazosin
Prazosin (INN)
Prazosin [INN:BAN]
Prazosin HCl
Prazosin HCL
Prazosin hydrochloride
Prazosin Hydrochloride
Prazosina
Prazosina [INN-Spanish]
Prazosine
Prazosine [INN-French]
Prazosinum
Prazosinum [INN-Latin]
Prestwick0_000947
Prestwick1_000947
Prestwick2_000947
Prestwick3_000947
SMP1_000063
SPBio_001297
SPBio_003073
Spectrum_000822
Spectrum2_001289
Spectrum3_000551
Spectrum4_000483
Spectrum5_001365
ST075549
STK301545
TL8001573
TNP00312
Tocris-0623
UNII-XM03YJ541D
Vasoflex
ZINC00601304
|
|
26 |
|
Iodine |
Approved, Investigational |
Phase 3 |
|
7553-56-2 |
807 |
Synonyms:
diiodine
I2
Iode
Iodine-molecule
Iodio
iodo
|
Iodum
Jod
Jood
molecular iodine
Molecular iodine
Tincture iodine
|
|
27 |
|
Miglustat |
Approved |
Phase 3 |
|
72599-27-0 |
51634 |
Synonyms:
(2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol
1,5-Dideoxy-1,5-N-butylimino-D-glucitol
134282-77-2
72599-27-0
AC1L1BHJ
BuDNJ
Butyldeoxynojirimycin
CHEBI:49779
CHEBI:50381
CHEMBL1029
CID51634
D05032
DB00419
HMS2090N20
LS-116261
Miglustat
Miglustat (USAN/INN)
Miglustat [USAN]
Miglustat, Hydrochloride
miglustatum
Miglustatum
N-(n-butyl)-1,5-dideoxy-1,5-imino-D-glucitol
N-(n-Butyl)deoxynojirimycin
N-(N-Butyl)deoxynojirimycin
|
N-(N-Butyl)deoxy-nojirimycin
NB-DNJ
N-Bu-DNJ
n-Butyl deoxynojirimycin
N-Butyl deoxynojirimycin
n-Butyl dnj
N-butyl-1-deoxynojirimycin
N-Butyl-1-deoxynojirimycin
N-Butyldeoxynojirimycin
N-Butyl-deoxynojirimycin
N-Butyl-DNJ
N-Butylmoranoline
NBV
nchembio.81-comp12
nchembio850-comp5
OGT 918
OGT-918
SC 48334
SC48334
SC-48334
UNII-ADN3S497AZ
Vevesca
Zavesca
Zavesca (TN)
|
|
28 |
|
mometasone furoate |
Approved, Investigational, Vet_approved |
Phase 3 |
|
83919-23-7 |
|
Synonyms:
|
Mometasone furoate anhydrous
|
|
29 |
|
Adrenergic alpha-Antagonists |
|
Phase 3 |
|
|
|
30 |
|
Antihypertensive Agents |
|
Phase 3 |
|
|
|
31 |
|
Adrenergic Antagonists |
|
Phase 3 |
|
|
|
32 |
|
Adrenergic alpha-1 Receptor Antagonists |
|
Phase 3 |
|
|
|
33 |
|
cadexomer iodine |
|
Phase 3 |
|
|
|
34 |
|
Hypoglycemic Agents |
|
Phase 3 |
|
|
|
35 |
|
Anti-Infective Agents |
|
Phase 3 |
|
|
|
36 |
|
Antiviral Agents |
|
Phase 3 |
|
|
|
37 |
|
Anti-HIV Agents |
|
Phase 3 |
|
|
|
38 |
|
Anti-Retroviral Agents |
|
Phase 3 |
|
|
|
39 |
|
Cardiac Glycosides |
|
Phase 3 |
|
|
|
40 |
|
Glycoside Hydrolase Inhibitors |
|
Phase 3 |
|
|
|
41 |
|
Parathyroid hormone |
Approved, Investigational |
Phase 2 |
|
9002-64-6 |
|
Synonyms:
Parathormone
Parathormone (human recombinant)
Parathyrin
Parathyroid hormone
Parathyroid hormone (1-84) human recombinant
Parathyroid hormone (rDNA)
|
PTH
PTH(1-84)
rhPTH
rhPTH(1-84)
rPTH
rPTH(1-84)
|
|
42 |
|
Indinavir |
Approved |
Phase 2 |
|
150378-17-9 |
5362440 |
Synonyms:
(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-pentonamide
(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-Pentonamide
(2S)-1-[(2S,4S)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide
150378-17-9
157810-81-6
157810-81-6 (sulfate (1:1) (salt))
166746-42-5
1c6y
1hsg
1hsh
1k6c
1sdt
1sdu
1sdv
1sgu
216884-06-9
2avo
2avs
2avv
2bpx
AC1L1U7I
AC-20034
AKOS000280989
BIDD:GT0378
BIDD:PXR0141
C07051
C36H47N5O4
CHEBI:44032
Compound J
|
Crixivan
Crixivan (TM)
DB00224
IDV
indinavir
Indinavir
Indinavir (*1:1 Sulfate salt*)
Indinavir [USAN]
Indinavir anhydrous
Indinavir sulfate
Indinavir sulphate
Indinavir, sulfate (1:1)
Indinavir, Sulfate (1:1)
L 735524
L-735 524
L-735,524
L-735524
LS-173382
MK-639
MolPort-000-883-804
N-[2(R)-HYDROXY-1(S)-INDANYL]-5-[(2(S)-TERTIARY BUTYLAMINOCARBONYL)-4(3-PYRIDYLMETHYL)PIPERAZINO]-4(S)-HYDROXY-2(R)-PHENYLMETHYLPENTANAMIDE
NCGC00159460-02
NSC697197
Propolis & 4-Hydroxy-N-(2-hydroxy-2,3-dihydro-1H-1-indanyl)-N'-(1,1-dimethylethyl)-2-phenylmethyl-5-[4-(3-pyridylmethyl)-1-piperzinyl]hexanediamide
Propolis+Indinavir
RS-253
Sulfate, indinavir
UNII-9MG78X43ZT
|
|
43 |
|
Ritonavir |
Approved, Investigational |
Phase 2 |
|
155213-67-5 |
392622 |
Synonyms:
1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
155213-67-5
1hxw
1sh9
538, ABT
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S)-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
A-84538
Abbott 84538
ABBOTT-84538
ABT 538
ABT 84538
ABT538
ABT-538
AC1L94GB
AC-733
AKOS000280930
BIDD:GT0387
BIDD:PXR0023
Bio-0093
C07240
C37H48N6O5S2
CHEBI:45409
CHEMBL163
CID392622
CPD000466395
D00427
D019438
DB00503
|
DRG-0244
FT-0082824
HMS2051B08
HSDB 7160
LS-148860
MLS000759541
MLS001424063
MolPort-000-883-877
N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N~2~-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide
NCGC00159462-02
Norvir
Norvir (TM)
Norvir (TN)
Norvir Sec
NSC693184
RIT
ritonavir
Ritonavir
Ritonavir (JAN/USAN/INN)
Ritonavir [USAN]
Ritonavir is an inhibitor of HIV protease used to treat HIV infection and AIDS.
Ritonavirum
RTV
S1185_Selleck
SAM001246783
SMR000466395
STK634209
ZINC03944422
|
|
44 |
|
Calcium carbonate |
Approved, Investigational |
Phase 2 |
|
471-34-1 |
|
Synonyms:
Calcio carbonato
Calcium carbonate (1:1)
Calciumcarbonat
Carbonate de calcium
Carbonato de calcio
|
Carbonic acid calcium salt (1:1)
Chalk
Kalziumkarbonat
Kohlensaurer kalk
Precipitated calcium carbonate
|
|
45 |
|
Everolimus |
Approved |
Phase 2 |
|
159351-69-6 |
70789204 6442177 |
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
001, RAD
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
40-O-(2-Hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
Certican
CERTICAN(R)
CHEMBL1201755
D02714
DB01590
everolimus
Everolimus
|
évérolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD, SDZ
RAD001
RAD-001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
RAD-001C
S1120_Selleck
SDZ RAD
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
|
|
46 |
|
Gefitinib |
Approved, Investigational |
Phase 2 |
|
184475-35-2 |
123631 |
Synonyms:
184475-35-2
4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
4-(3'-chloro-4'-fluoroanilino)-7-Methoxy-6-(3-morpholinopropoxy)quinazoline
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine
AC-1556
AC1L3X0A
AKOS000280752
BCB03_000781
Bio-0046
C419708
CCRIS 9011
CHEBI:49668
CHEMBL939
CID123631
CU-00000000396-1
D01977
DB00317
DB07998
EC-000.2409
EN002708
FT-0081035
Gefitini
gefitinib
Gefitinib
Gefitinib (JAN/USAN/INN)
Gefitinib [USAN]
Gefitinib, Iressa, ZD1839
Gelfitinib
HMS2089B19
I01-1227
IRE
|
Iressa
Iressa (TN)
Iressa(TM)
Irressat
K00240
KBioSS_002241
Kinome_3321
Kinome_3322
LS-139916
MolPort-000-883-335
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
N-(3-chloro-4-Fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
N-(3-chloro-4-Fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine
NCGC00159455-02
NCGC00159455-03
nchembio.117-comp18
nchembio866-comp14
NSC715055
S1025_Selleck
STK621310
UNII-S65743JHBS
ZD 1839
ZD1839
ZD-1839
ZD-1839, Iressa, Gefitinib
ZINC19632614
|
|
47 |
|
Celecoxib |
Approved, Investigational |
Phase 2 |
|
169590-42-5 |
2662 |
Synonyms:
169590-42-5
184007-95-2
1oq5
4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide
4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE
4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
AC1L1E6K
AC-4228
AI-525
Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)
BIDD:GT0408
BRD-K02637541-001-02-4
BSPBio_003596
C07589
C105934
C17H14F3N3O2S
CCRIS 8679
CEL
Celebra
Celebrex
Celebrex (TN)
Celebrex, Celebra, Celecoxib
Celecox
Celecoxi
celecoxib
Celecoxib
Célécoxib
Celecoxib (JAN/USAN/INN)
Celecoxib (SC-58635)
Celecoxib [Old RN]
Celecoxib [USAN]
Celecoxibum
Celocoxib
CEP-33222
CHEBI:41423
CHEMBL118
CID2662
cMAP_000027
CPD000550473
D00567
DB00482
DivK1c_000893
Eurocox
FT-0080064
HMS1922G14
HMS2089L18
HMS2093I07
HMS502M15
HSDB 7038
I01-1033
IDI1_000893
KBio1_000893
|
KBio2_000912
KBio2_002351
KBio2_003480
KBio2_004919
KBio2_006048
KBio2_007487
KBio3_002830
KBio3_003037
KBioGR_000723
KBioGR_002351
KBioSS_000912
KBioSS_002354
LS-31667
Medicoxib
MLS001165684
MLS001195656
MLS001304708
MolPort-002-885-815
NCGC00091455-01
NCGC00091455-02
NCGC00091455-03
NCGC00091455-04
NCI60_041049
NINDS_000893
NSC719627
Onsenal
p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
P-(5-P-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
P-(5-P-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulphonamide
Pfizer brand of celecoxib
S1261_Selleck
SAM002589995
SC 58635
SC-58553, SC-58635
SC58635
SC-58635
SMR000550473
Solexa
SPBio_001512
Spectrum_000432
SPECTRUM1503678
Spectrum2_001576
Spectrum3_001996
Spectrum4_000182
Spectrum5_001324
TL8001323
TPI-336
UNM-0000305813
Xilebao
YM 177
YM177
YM-177
ZINC02570895
|
|
48 |
|
Romidepsin |
Approved, Investigational |
Phase 2 |
|
128517-07-7 |
5352062 |
Synonyms:
(1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone
(1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone
(1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone
128517-07-7
AC1NS1N3
Antibiotic FR 901228
C087123
C24H36N4O6S2
CHEBI:61080
CHEMBL343448
Chromadax
Chromadax (TN)
CID5352062
Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (3?5)-disulfide"
D06637
FK 228
FK228
FK-228
FK-901228
|
FR 901228
FR901228
FR-901228
HDInhib_000006
Istodax
LS-161318
L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide
nchembio.313-comp2
NSC 630176
NSC630176
NSC-630176
Probes1_000153
Probes2_000337
Romidepsin
Romidepsin (USAN)
Romidepsina
Romidepsine
Romidepsinum
|
|
49 |
|
Cetuximab |
Approved |
Phase 2 |
|
205923-56-4 |
56842117 2333 |
Synonyms:
205923-56-4
Anti EGFR
cetuximab
Cetuximab
Cétuximab
Cetuximab (genetical recombination)
Cetuximab (genetical recombination) (JAN)
|
Cetuximab (USAN/INN)
Cetuximabum
D03455
Erbitux
Erbitux (TN)
IMC-C225
|
|
50 |
|
Decitabine |
Approved, Investigational |
Phase 2 |
|
2353-33-5 |
451668 |
Synonyms:
2353-33-5
2'-Deoxy-5-azacytidine
4-amino-1-(2-Deoxy-b-D-erythro-pentofuranosyl)-S-triazin-2(1H)-one
4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one
4-amino-1-(2-Deoxy-beta-D-erythro-pentofuranosyl)-S-triazin-2(1H)-one
4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-s-triazin-2(1H)-one
4-Amino-1-(2-deoxy-beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one
4-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-s-triazin-2(1H)-one
4-amino-1-(2-Deoxy-β-D-erythro-pentofuranosyl)-S-triazin-2(1H)-one
4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one
5A2dc
5-Aza-2&prime
5-aza-2'-deoxycytidine
5-aza-2-deoxycytidine
5-Aza-2'-deoxycytidine
5-aza-CdR
5-aza-dC
5-AZAdC
5-azadeoxycytidine
5-Azadeoxycytidine
5-Deoxy-2&prime
5-Deoxyazacytidine
A3656_SIGMA
AC-1135
AC1L9PS9
-azacytidine
Azadc
AzadC
|
AzadC compound
CHEBI:50131
CHEMBL1201129
CID451668
D03665
DAC
Dacogen
Dacogen (TN)
Dacogen, 5-aza-2'-deoxycytidine,NSC 127716, Dacogen, DAC, Decitabine
DB01262
Decitabina
Decitabine
Decitabine (USAN/INN)
Decitabine mesylate
-Deoxycytidine
Dezocitidine
E-7373
FT-0082622
MLS001332587
MLS001332588
MolMap_000063
NCGC_5ADOC
NSC127716
NSC-127716
S1200_Selleck
SBB066121
SMR000857076
TL8001944
|
|
Interventional clinical trials:
(show top 50)
(show all 241)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A-PACT: The Use of Inhaled Aztreonam to Eliminate or Decrease the Bacterial Burden of Pseudomonas Aeruginosa in Children With a Tracheostomy Tube. |
Unknown status |
NCT03158116 |
Phase 4 |
Inhaled Aztreonam |
2 |
IN-PACT CORO INtimal hyPerplasia evAluated by oCT in de Novo COROnary Lesions Treated by Drug-eluting Balloon and Bare-metal Stent |
Unknown status |
NCT01057563 |
Phase 4 |
|
3 |
Feasibility of a Personalised Medicine Clinic for Children With Asthma Aged 5-11 Years |
Terminated |
NCT03269318 |
Phase 4 |
Montelukast or Salmeterol or Theophylline or Steroid |
4 |
Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma: A Prospective Randomized Controlled Trial |
Completed |
NCT00795782 |
Phase 3 |
|
5 |
Value of Sentinel Lymph Node Biopsy to Lateral Neck Lymph Node in Thyroid Carcinoma: Prospective Study |
Completed |
NCT01137097 |
Phase 2, Phase 3 |
|
6 |
Follow-up of Thyroid Cancer Patients From Study THYR-008-00 Who Received Thyroid Remnant Ablation Using Either the Hypothyroid or the Thyrogen Method. |
Completed |
NCT00295763 |
Phase 3 |
Thyrogen (thyrotropin alfa for injection) |
7 |
Decision Aid on Radioactive Iodine Treatment for Early Stage Papillary Thyroid Cancer (Randomized Controlled Trial) |
Completed |
NCT01083550 |
Phase 2, Phase 3 |
|
8 |
Non-small Cell Lung Cancer Study US75 (Z-PACT) |
Completed |
NCT00086268 |
Phase 3 |
zoledronic acid;Taxotere;Carboplatin |
9 |
Pediatric Asthma Controller Trial (PACT) |
Completed |
NCT00272506 |
Phase 3 |
inhaled corticosteroid;long-acting beta2-agonist |
10 |
Developing a Patient Inventory to Facilitate Patient-centered Care Delivery |
Completed |
NCT01843803 |
Phase 2, Phase 3 |
|
11 |
CSP #563 - Prazosin and Combat Trauma PTSD (PACT) |
Completed |
NCT00532493 |
Phase 3 |
prazosin |
12 |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-Targeted Therapy |
Recruiting |
NCT03690388 |
Phase 3 |
Cabozantinib;Placebo |
13 |
Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients |
Recruiting |
NCT01398085 |
Phase 2, Phase 3 |
|
14 |
Sentinel Lymph Node Biopsy in the Thyroid Carcinoma; Randomized, Prospective Study |
Recruiting |
NCT01149161 |
Phase 2, Phase 3 |
|
15 |
Models of Primary Osteoporosis Screening in Male Veterans |
Recruiting |
NCT04079868 |
Phase 2, Phase 3 |
|
16 |
Multicentre Randomised Trial of High Dose Versus Low Dose Radioiodine, With or Without Recombinant Human Thyroid Stimulating Hormone, for Remnant Ablation Following Surgery for Differentiated Thyroid Cancer [HILO] |
Active, not recruiting |
NCT00415233 |
Phase 3 |
|
17 |
A Phase 3 Double-blind Randomized Study to Assess the Efficacy and Safety of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late Onset Pompe Disease Compared With Alglucosidase Alfa/Placebo |
Active, not recruiting |
NCT03729362 |
Phase 3 |
AT2221 |
18 |
ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer |
Not yet recruiting |
NCT03570021 |
Phase 3 |
|
19 |
A Phase II Study to Investigate the Efficacy of RAD001 (Afinitor®, Everolimus) in Patients With Irresectable Recurrent or Metastatic Differentiated, Undifferentiated (Anaplastic) and Medullary Thyroid Carcinoma |
Unknown status |
NCT01118065 |
Phase 2 |
everolimus |
20 |
A Pilot Study of Rosiglitazone in Patients With Incurable Differentiated Thyroid Cancer |
Unknown status |
NCT00098852 |
Phase 2 |
rosiglitazone maleate |
21 |
Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study |
Unknown status |
NCT00637637 |
Phase 2 |
indinavir sulfate;ritonavir |
22 |
Phase 2 Study of Selumetinib Hydrogen Sulfate in Iodine-131 Refractory Papillary Thyroid Carcinoma and Papillary Thyroid Carcinoma With Follicular Elements |
Completed |
NCT00559949 |
Phase 2 |
Selumetinib |
23 |
Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy |
Completed |
NCT01811212 |
Phase 2 |
Cabozantinib S-malate |
24 |
An Open-Label, Multi-Center Phase II Study of the BRAF Inhibitor Vemurafenib in Patients With Metastatic or Unresectable Papillary Thyroid Cancer (PTC) Positive for the BRAF V600 Mutation and Resistant to Radioactive Iodine |
Completed |
NCT01286753 |
Phase 2 |
Vemurafenib |
25 |
Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma |
Completed |
NCT00887107 |
Phase 2 |
Sorafenib (nexavar) |
26 |
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma |
Completed |
NCT01502410 |
Phase 2 |
sorafenib tosylate |
27 |
Phase 2 Study of Routine Oral Calcium and Vitamine D Supplements to Prevent Hypocalcemia After Total Thyroidectomy in Papillary Thyroid Carcinoma Patients |
Completed |
NCT00630214 |
Phase 2 |
|
28 |
A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer |
Completed |
NCT00121628 |
Phase 2 |
AMG 706 |
29 |
An Open Label Multi-Center Phase II Study of RAD001 in Advanced Thyroid Cancer |
Completed |
NCT01164176 |
Phase 2 |
everolimus |
30 |
A Phase II Study of ZD 1839 (IRESSA®) in Patients With Advanced Thyroid Cancer |
Completed |
NCT00095836 |
Phase 2 |
Gefitinib |
31 |
Phase II Study Of Celecoxib In Metastatic Differentiated Thyroid Carcinoma |
Completed |
NCT00061906 |
Phase 2 |
celecoxib |
32 |
A Phase II Study of Single Agent Depsipeptide (FK228) in Radioiodine (RAI)-Refractory Metastatic Non-medullary (Papillary, Follicular, and Hurthle Cell Variants) Thyroid Carcinoma |
Completed |
NCT00098813 |
Phase 2 |
romidepsin |
33 |
An Open-label, Phase II Study of Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers |
Completed |
NCT01524978 |
Phase 2 |
cetuximab;vemurafenib;vemurafenib |
34 |
Phase II Study of Decitabine in Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Radioiodine |
Completed |
NCT00085293 |
Phase 2 |
Decitabine |
35 |
Sutent Adjunctive Treatment of Differentiated Thyroid Cancer |
Completed |
NCT00668811 |
Phase 2 |
SU011248, Sutent |
36 |
A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma |
Completed |
NCT00104871 |
Phase 2 |
Bortezomib |
37 |
Phase II Trial of Thalidomide for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas and Medullary Thyroid Carcinomas |
Completed |
NCT00026533 |
Phase 2 |
thalidomide |
38 |
A Broad Multi-Histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-Small Cell Lung, Head and Neck, Hepatocellular and Renal Cell Carcinomas and Pheochromocytoma and Thyroid Tumors |
Completed |
NCT00923481 |
Phase 2 |
Fostamatinib disodium |
39 |
Randomized Controlled Trial of Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in Patients With Low-risk Papillary Thyroid Cancer |
Completed |
NCT02408887 |
Phase 2 |
|
40 |
Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies |
Completed |
NCT00002608 |
Phase 2 |
cisplatin;doxorubicin hydrochloride;tamoxifen citrate |
41 |
A Randomized, Multicenter, Open-label, Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma |
Completed |
NCT01813136 |
Phase 2 |
Continuous pazopanib (Arm A);Intermittent pazopanib (Arm B) |
42 |
A Phase II Study of Single Agent Intravenous (IV) VEGF Trap in Patients With Poor Prognostic Recurrent and/or Metastatic Thyroid Cancer After RAI Therapy |
Completed |
NCT00729157 |
Phase 2 |
|
43 |
Vaccine Therapy With Tumor Specific Mutated Ras Peptides and IL-2 or GM-CSF for Adult Patients With Solid Tumors |
Completed |
NCT00019331 |
Phase 2 |
DetoxPC |
44 |
The Participant Agreement for Contact Tracing (PACT) Study: Enhancing Partner Notification Services. |
Completed |
NCT00207493 |
Phase 1, Phase 2 |
|
45 |
A Phase 1/2, Open-Label, Dose-Escalation And Expansion Study Of Entrectinib (Rxdx-101) In Pediatrics With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options |
Recruiting |
NCT02650401 |
Phase 1, Phase 2 |
Entrectinib |
46 |
A Phase 1/2 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AO-176 |
Recruiting |
NCT03834948 |
Phase 1, Phase 2 |
AO-176 |
47 |
A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma - The DUTHY Trial |
Recruiting |
NCT03753919 |
Phase 2 |
Durvalumab;Tremelimumab |
48 |
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements |
Recruiting |
NCT02568267 |
Phase 2 |
Entrectinib |
49 |
A Phase 2 Study of Lenvatinib in Combination With Radioactive Iodine Therapy in Patients With Progressive RAI-Sensitive Differentiated Thyroid Cancer |
Recruiting |
NCT03506048 |
Phase 2 |
Lenvatinib |
50 |
A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors |
Recruiting |
NCT03899792 |
Phase 1, Phase 2 |
LOXO-292 |
|